NOVAVAX INC

NVAXNASDAQ

🏆 #1909 by market capEarnings Nov 5US Equity

$379.35▲ $20.11 (+5.30%)

Simulated price

1h—

24h▲ 5.3%

7d▲ 4820.2%

14d▲ 5071.8%

30d▲ 4157.6%

1y▲ 4368.2%

🏦Market Cap

$1.31B

Small Cap

📈Revenue Growth (YoY)

+64.7%

High Growth

📊Gross Margin

77.8%

High

💵FCF Margin

-10.5%

Thin

⚖️P/S Ratio

3.2x

Fair

Otter Score

Fair

Trading Snapshot

Day Range: $373.61 – $385.18
52-Week Range: $6.20 – $11.97
Volume: $1.72B
Avg Volume: $2.12B
Shares Outstanding: 164.4M
Next Earnings: Oct 20, 2026

Fundamentals Snapshot

Annual Revenue: $1.12B
Last Q Revenue: $57M
P/E Ratio: -5.2
P/S Ratio: 3.2x
EPS (TTM): $-1.51
Dividend Yield: 0.00%

Why Investors Own NVAX

✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
✓Healthy economics — 49% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$1.12B▲ +28.3% YoY

Gross Margin (TTM)

48.9%▲ +0.8% YoY

Operating Income (TTM)

$249M▲ +28.3% YoY

Free Cash Flow (TTM)

$227M▲ +28.3% YoY

About NOVAVAX INC

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

🦦